LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

LLY

991.54

+0.35%↑

JNJ

224.8

+1.37%↑

ABBV

207.81

+2%↑

UNH

386.61

+1.48%↑

AZN

184.22

-0.29%↓

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Atvērts

SektorsVeselības aprūpe

14.22 -9.25

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.11

Max

15.86

Galvenie mērījumi
By Trading Economics
Ienākumi	3.9M 4.5M
Pārdošana	5.9M 24M
EPS	0.35
Dividenžu ienesīgums	0.48
Peļņas marža	18.669
Darbinieki	212
EBITDA	4.9M 7.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-4.08% downside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.48% 2.25%
Nākamie ieņēmumi	2026. g. 13. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	55M 306M
Iepriekšējā atvēršanas cena	23.47
Iepriekšējā slēgšanas cena	14.22

Ziņu noskaņojums

By Acuity

95%

2 / 346 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. maijs 22:15 UTC

Iegādes, apvienošanās, pārņemšana

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026. g. 11. maijs 23:46 UTC

Tirgus saruna

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026. g. 11. maijs 23:44 UTC

Tirgus saruna

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026. g. 11. maijs 23:33 UTC

Tirgus saruna

Gold Rises on Possible Position Adjustments -- Market Talk

2026. g. 11. maijs 22:37 UTC

Tirgus saruna

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026. g. 11. maijs 22:32 UTC

Peļņas

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026. g. 11. maijs 22:02 UTC

Tirgus saruna

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026. g. 11. maijs 21:49 UTC

Peļņas

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026. g. 11. maijs 21:42 UTC

Tirgus saruna

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026. g. 11. maijs 21:31 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026. g. 11. maijs 21:23 UTC

Iegādes, apvienošanās, pārņemšana

CSG Systems Sale to NEC Gets CFIUS Clearance

2026. g. 11. maijs 21:12 UTC

Peļņas

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026. g. 11. maijs 21:12 UTC

Peļņas

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026. g. 11. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 11. maijs 20:44 UTC

Peļņas

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026. g. 11. maijs 20:43 UTC

Peļņas

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026. g. 11. maijs 20:32 UTC

Peļņas

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026. g. 11. maijs 20:32 UTC

Peļņas

CleanSpark 2Q Rev $136.4M >CLSK

2026. g. 11. maijs 20:30 UTC

Peļņas

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Cont Ops EPS $2.24 >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Rev $1.6B >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Adj EPS $2.83 >STE

2026. g. 11. maijs 20:22 UTC

Karstas akcijas

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026. g. 11. maijs 19:37 UTC

Peļņas

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026. g. 11. maijs 19:32 UTC

Tirgus saruna

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-4.08% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD -4.08%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

2 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.